Publications:105
Noura S Abul-Husn, MD, PhD
About Me
Noura S. Abul-Husn, MD, PhD is an Associate Professor of Medicine with expertise in genomic medicine and personalized healthcare. She is board certified in Internal Medicine and Medical Genetics.
Dr. Abul-Husn is a physician-scientist working to uncover the clinical impact of human genetic variation in diverse populations and drive the equitable implementation of genomic medicine. She previously served as the founding Chief of the Division of Genomic Medicine in the Department of Medicine, and founding Clinical Director of the Institute for Genomic Health. In these roles, she developed a genomic screening program tailored to ancestrally diverse populations, launched the Genomic Health Clinic to provide the clinical infrastructure for emerging genomic applications, and created the Genomic Medicine Track for Internal Medicine residents to expand genomics knowledge across medical specialties.
Dr. Abul-Husn’s scientific contributions include pioneering genome-first approaches to provide novel clinical insights and inform therapeutic discovery. She is an expert at leveraging large-scale genomic data linked to electronic health records, and her work has been published in leading journals, including Science, Cell, and the New England Journal of Medicine. As a principal investigator in the NIH/NHGRI-funded eMERGE (electronic Medical Records and Genomics) Network, she is leading efforts to integrate genomic risk information into clinical care for diverse patient populations.
Dr. Abul-Husn completed her MD, PhD, and residency in Internal Medicine and Medical Genetics at the Icahn School of Medicine at Mount Sinai and was elected to the Alpha Omega Alpha Medical Honor Society. She is the recipient of numerous awards, including a Westchester’s 40 under 40 Rising Star Award and the Dr. Michael S. Watson Genetic & Genomic Medicine Innovation Award from the ACMG Foundation for Genetic and Genomic Medicine.
Language
English
Position
ASSOCIATE CLINICAL PROFESSOR | Medicine, Medical Genomics
Research Topics
Clinical Genomics, Genetics, Genomics
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Genetics and Genomic Sciences [GGS]
Clinical Focus
- Genetic Counseling
Video
Education
MD, Icahn School of Medicine at Mount Sinai
PhD, Icahn School of Medicine at Mount Sinai
Publications
Selected Publications
- Association of high and moderate penetrance monogenic variants, polygenic risk, and family history with breast cancer in an ancestrally diverse population. Emily R. Soper, Nicole A. Casasanta, Bethany Dubois, Gillian M. Belbin, Eimear E. Kenny, Noura S. Abul-Husn. Cancer genetics
- Publisher Correction: Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction (Nature Genetics, (2026), 58, 5, (1030-1039), 10.1038/s41588-026-02576-0). Fei Fei Cheng, Xiaoxi Liu, Hao Mi, Lizhong Wang, Ruilei Ma, Yazhou Guo, Julia Sidorenko, Chen Jiang, Tania Islam, Akira Meguro, Keiko Hikino, Yuki Ishikawa, Senwei Tang, Teng Li, Ruoyan Chen, Likun Wang, Reedik Mägi, Andres Metspalu, Georgi Hudjashov, Mari Nelis, Tõnu Esko, Lili Milani, William A. Freyman, Steven J. Micheletti, Peter R. Wilton, Jingran Wen, James R. Ashenhurst, G. David Poznik, Ethan M. Jewett, Éadaoin Harney, Chris German, Bertram L. Koelsch, Anna Guan, Aditya Ambati, Stacey B. Detweiler, Ruth I. Tennen, Rebecca M.K. Berns, R. Ryanne Wu, Noura S. Abul-Husn, Alisa P. Lehman, Wanwan Xu, Vinh Tran, Stella Aslibekyan, Shubham Saini, Sayantan Das, Robert K. Bell, Qiaojuan Jane Su, Matthew J. Kmiecik, Matthew H. McIntyre, Keng Han Lin. Nature Genetics
- Genetic predictors of GLP1 receptor agonist weight loss and side effects. Qiaojuan Jane Su, James R. Ashenhurst, Wanwan Xu, Vinh Tran, R. Ryanne Wu, Catherine H. Weldon, Jingchunzi Shi, Barry Hicks, Joyce Y. Tung, Teague Sterling, Suyash Shringarpure, Anjali J. Shastri, Shubham Saini, Carrie Northover, Alex Moran, Matthew H. McIntyre, Keng Han Lin, Yanyu Liang, Alan Kwong, Matthew J. Kmiecik, Aly Khan, Reza Jabal, David A. Hinds, Larry Hengl, Julie M. Granka, Chris German, Shirin Fuller, Sarah L. Elson, Chris Eijsbouts, Emily DelloRusso, Payambr Dibaeinia, Devika Dhamija, Kahsaia de Brito, Sayantan Das, Zayn Cochinwala, Katelyn Kukar Bond, Robert K. Bell, Noura S. Abul-Husn, Stella Aslibekyan, Michael V. Holmes, Bertram L. Koelsch, Adam Auton. Nature
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Abul-Husn during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Inflection Medicine
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- Inflection Medicine
Outside Employment
- 23andMe Research Institute
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.